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Transporters are important therapeutic but yet understudied targets due to lack of available assays. 
Here we describe a novel label-free, whole-cell method for the functional assessment of Solute Carrier 
(SLC) inhibitors. As many SLC substrates are also ligands for G protein-coupled receptors (GPCRs), 
transporter inhibition may affect GPCR signalling due to a change in extracellular concentration of 
the substrate/ligand, which can be monitored by an impedance-based label-free assay. For this study, 
a prototypical SLC/GPCR pair was selected, i.e. the equilibrative nucleoside transporter-1 (SLC29A1/
ENT1) and an adenosine receptor (AR), for which adenosine is the substrate/ligand. ENT1 inhibition 
with three reference compounds was monitored sensitively via AR activation on human osteosarcoma 
cells. Firstly, the inhibitor addition resulted in an increased apparent potency of adenosine. Secondly, all 
inhibitors concentration-dependently increased the extracellular adenosine concentration, resulting in 
an indirect quantitative assessment of their potencies. Additionally, AR activation was abolished by AR 
antagonists, confirming that the monitored impedance was AR-mediated. In summary, we developed a 
novel assay as an in vitro model system that reliably assessed the potency of SLC29A1 inhibitors via AR 
signalling. As such, the method may be applied broadly as it has the potential to study a multitude of 
SLCs via concomitant GPCR signalling.
Solute carriers (SLCs) are transmembrane transport proteins that control a cell’s intra- and extracellular commu-
nication with its environment by regulating the translocation of small molecules, inorganic ions or other proteins 
across biological membranes. Their function as gatekeepers, their ubiquitous presence in the human body, and 
the large number of SLCs (more than 400) render them potential therapeutic targets1. However, their in-depth 
investigation has been limited as not many cellular assays are available to study transporter activity, making 
drug discovery difficult. The main and most well-known assay format currently used is the uptake assay, which 
measures the accumulation of a radiolabeled substrate in cells expressing the transporter under investigation2. 
Such assay however, presents limitations as only the end-point of the assay can be measured and/or washing steps 
are needed, which make this type of assay laborious and prone to artefacts. Moreover, the need for radioactive 
substrates has disadvantages, such as high costs, handling of radioactivity and storage of radioactive waste3. In 
addition, label-free electrophysiological methods have been applied and many electrogenic SLCs, i.e. transporters 
the function of which results in a positive or negative intracellular net charge, have been studied as such (Grewer 
et al. 2013)4. The best-known electrophysiological technique is patch-clamp, a well-studied concept that meas-
ures the direct current generated by ions that flow through the transporters, with a plethora of instruments being 
commercially available (Priest et al. 2004)5. In addition to patch-clamp, solid supported membrane (SSM)-based 
electrophysiology has been applied to transporters as a more sensitive approach, where SURFE²R N1 (Nanion 
Technologies) is the main instrumentation used6. However, no label-free assays applicable to non-electrogenic 
membrane transporters, which represent the majority of SLCs are available. Therefore, the development of a 
homogenous, kinetic and label-free assay in the field of non-electrogenic membrane transporter research is of 
utmost interest.
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Label-free whole cell assays typically use a biosensor that detects physical properties of cells, such as size, 
adhesion and morphology, in order to measure cellular responses upon ligand stimulation7. The main advan-
tage of using biosensors and cell morphology to functionally assess a ligand-target interaction is that cells are 
monitored in real time and in high sensitivity, making it possible to study cell systems with endogenous target 
expression8,9. As a result, no modification of the cells, for example transfection of an (engineered) target into an 
artificial cell line, or the compounds, i.e. with a fluorescent or radioactive tag, is necessary, which avoids potential 
artefacts10. Over the last decade, the number of available label-free cellular assays has significantly increased, 
and many of these have been used to study G protein-coupled receptor (GPCR) signalling11,12. Examples are the 
EPIC (Corning Inc.) and xCELLigence (ACEA Biosciences), which measure cell morphology optically and by 
impedance, respectively. However, the use of label-free assays are still rather unexploited, if at all, for membrane 
transporters.
ENT1 (also known as SLC29A1) is the most abundant nucleoside transport (NT) protein in the human 
body13. This SLC plays a crucial role in the provision of nucleosides, as it participates in the salvage pathways of 
nucleotide synthesis in cells lacking de novo biosynthetic pathways14. Therapeutically, ENT1 can be targeted by 
drugs that are both substrates and inhibitors. In the cases of viral infections and in some types of cancer, ENT1 
transports well-known drugs inside the cell in order to exert their action, e.g. gemcitabine and ribavirin, respec-
tively15,16. As far as ENT1 inhibition is concerned, molecules that diminish ENT1 activity are proposed as an 
add-on treatment of cancer, whenever ENT1 is overexpressed17. Moreover, ENT1 inhibitors can potentially be 
used in the treatment of ischemic heart disease18, stroke19 and inflammatory diseases20. Of note, in many cases the 
therapeutic effect of ENT1 inhibitors is induced by adenosine21, as its increased extracellular concentration can 
potentiate neuroprotective and cardioprotective actions resulting from the activation of neighbouring adenosine 
receptors (ARs).
In the current study, we describe the development of a novel cellular assay for the functional assessment of 
SLC activity by using the label-free impedance-based xCELLigence instrument. Many endogenous substrates of 
membrane transporters are also ligands for GPCRs, e.g glutamate, dopamine and adenosine22,23. Thus, we hypoth-
esized that by inhibiting a transporter, the substrate concentration would increase outside of the cell, resulting in 
increased GPCR signalling that is subsequently monitored with the xCELLigence (Fig. 1). For proof-of-principle, 
we investigated the inhibition of ENT1 transporters by well-known ENT1 inhibitors, and monitored concomitant 
adenosine receptor signalling. For validation purposes we performed radioligand binding studies on SLC29A1 
as well.
Figure 1. Assay principle. ENT1 equilibrates adenosine concentrations inside and outside of the cell 
membrane. Extracellular adenosine binds to ARs and causes their activation and signalling (black arrows). After 
treatment with an ENT1 inhibitor, adenosine cannot be translocated intracellularly with the same efficiency, 
depending on inhibitor’s inhibitory potency and concentration. The resulting higher extracellular adenosine 
concentration will cause increased AR activation (thicker arrows).
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Results
Assay development and optimization. To confirm the suitability of U-2 OS cells for studying ENT1 
function via AR signalling, we performed a radioligand binding assay on U-2 OS membranes. U-2 OS mem-
branes were incubated with [3H]NBTI and increasing concentrations of reference inhibitors, i.e. NBTI, dilazep 
and dipyridamole. All inhibitors fully displaced the radioligand from the ENT1. NBTI had the highest affin-
ity (pKi = 8.7 ± 0.02), followed by dilazep (pKi = 8.5 ± 0.1) and dipyridamole (pKi = 7.2 ± 0.1) (Supplementary 
Material; Fig. S1 and Table S1).
Subsequently, U-2 OS whole cells were used to monitor the inhibitors’ activity in the impedance-based 
label-free technology. U-2 OS cells adhered strongly to the bottom of the wells and thus the gold-coated elec-
trodes of the E-plates, and therefore no additional coating was necessary to obtain a signal. Various concentra-
tions of cells per well were tested in order to achieve a uniform cell monolayer (Supplementary Material; Fig. S2), 
which was the case for a concentration of 20,000 cells/well. After cell seeding, attachment, spreading and over-
night proliferation, this concentration resulted in a cell index (CI) ranging from 10.0 to 12.0 (Fig. 2A,B). Thus, 
Figure 2. Concentration-dependent effects of adenosine (Ado) after cell pre-treatment with a single 
concentration of ENT1 inhibitors (“Format 1”). (A) Graphic representation of cell seeding, spreading, pre-
treatment and treatment protocol. (B) Representative xCELLigence traces of a full experiment when cells 
were pre-treated with NBTI (10−6 M) and subsequently stimulated with adenosine. A representative response 
(C) after NBTI, dilazep, dipyridamole pre-treatment and (D) after adenosine treatment of cells pre-treated 
with NBTI. (E) Concentration-response curves for adenosine with or without ENT1 inhibitors pre-treatment 
(adenosine 10−3.5 M response as 100%). Data shown are mean ± SEM from at least three separate experiments 
performed in duplicate.
4Scientific RepoRtS |         (2019) 9:13802  | https://doi.org/10.1038/s41598-019-48829-3
www.nature.com/scientificreportswww.nature.com/scientificreports/
20,000 cells/well was selected for all further experiments, as it allowed reliable and reproducible measurements of 
ENT1 inhibition and subsequent AR activation.
Validation of the Assay Principle. For the development of the label-free assay, we hypothesized that ENT1 
inhibition can be detected via adenosine receptor signalling, due to changes in the extracellular concentration of 
adenosine.
Firstly, it was examined if ENT1 inhibition would lead to an increased extracellular adenosine concentra-
tion. Hence, cells were pre-treated with a single concentration (10−6 M) of an ENT1 inhibitor and subsequently 
treated with several concentrations of adenosine (i.e. “Format 1”). Upon pre-treatment of cells for 30 min with a 
single concentration of an inhibitor (10−6 M) no change of impedance (expressed as ΔCl) was detected (Fig. 2C). 
On the contrary, subsequent treatment of cells with various concentrations of adenosine led to a decrease of 
ΔCl (Fig. 2D). Specifically, the signal decreased in a concentration-dependent manner reaching a minimum 
ranging from −0.5 to −1.5 ΔCl after approximately 8 to 10 min. The initial decrease in ΔCI was followed by a 
slow increase back to baseline within 90 min. From these impedance changes, the AUC was determined and a 
concentration-response curve was obtained providing apparent potency values of adenosine for AR signalling 
after pre-treatment with vehicle and NBTI, dilazep and dipyridamole, i.e. pEC50 values of 4.2 ± 0.1, 4.9 ± 0.1, 
5.1 ± 0.1, 5.2 ± 0.1, respectively (Fig. 2E and Table 1).
Next, to confirm that the observed changes in impedance and the pEC50 values of adenosine are AR-specific, 
we used CGS 15943 as a non-selective AR antagonist and PSB 1115 as a selective A2B AR antagonist. Cells were 
pre-treated with either CGS 15943, NBTI and PSB 1115 or a combination of the first two. Upon pre-treatment 
for 30 min with each of the compounds no change of impedance was detected (data not shown). As observed 
in Fig. 2D, pre-treatment with NBTI and the consecutive treatment with adenosine led to an increased AUC 
(219 ± 7.3%) (Fig. 3; Table 1). In contrast, pre-treatment with CGS 15943 followed by adenosine stimulation 
resulted in a cellular response with a strongly diminished AUC (29.4 ± 9%) (Fig. 3). Interestingly, when cells were 
simultaneously pre-treated with CGS 15943 and NBTI, an AUC similar to pre-treatment with CGS 15943 alone 
was observed (42.2 ± 16%) (Fig. 3). This result indicates that the increased extracellular concentration of adeno-
sine, caused by NBTI inhibition of ENT1, cannot generate an increased cellular response when ARs are blocked 
by CGS 15943. Similarly, pre-treatment of cells with PSB 1115 resulted in a decreased AUC (18.5 ± 5.4%) (Fig. 3), 
indicating the A2B AR to be the most prevalent AR. Taken together, this shows that inhibition of ENT1 results in 
an increased apparent potency for adenosine-mediated AR signalling.
Pharmacological characterization of ENT1 inhibitors in U-2 OS cells using the xCELLi-
gence. Lastly, the inhibitory effect of different known ENT1 inhibitors was evaluated in a different assay set 
up (i.e. “Format 2”). Cells were pre-treated with increasing concentrations of NBTI, dilazep and dipyridamole 
ranging from 10−11 to 10−6 M. Successive addition of a fixed concentration of adenosine (30 μM) led to a negative 
response with a peak around 8 to 10 minutes depending on the concentration of the inhibitor. This phase was 
followed by an increase of the response that in all cases reached plateau within 90 minutes after the adenosine 
addition (Fig. 4A–C). Of note, the shape of these traces were similar for all experimental set-ups, indicative for 
a typical signature of adenosine-mediated AR signalling in U-2 OS cells. Moreover, all compounds appeared 
to enhance the adenosine-mediated AR signalling in a concentration-dependent manner as higher concentra-
tions of the inhibitors seem to decrease further the ΔCI especially after the initial negative peak is reached. 
Interestingly, pre-treatment with various concentrations of dipyridamole generated a negative response with a 
significantly higher inhibitory efficacy (% AUC at 1 µM) compared to dilazep and NBTI. In conclusion, using this 
assay set up an ENT1 inhibitor’s potency and inhibitory efficacy could be obtained. Furthermore, different ENT1 
inhibitors have different potencies for indirectly inhibiting adenosine-mediated AR signalling.
Format 1 Format 2
Adenosine 
pEC50 ± SEMa





vehicle 1 4.2 ± 0.1 n.a. 100 ± 5.6
+NBTI 4.9 ± 0.1 **** 8.3 ± 0.3 (2.6) 219 ± 7.3****
+Dilazep 5.1 ± 0.1 **** 10.1 ± 0.1 (0.1) 286 ± 19****
+Dipyridamole 5.2 ± 0.1 **** 8.6 ± 0.5 (8.1) 525 ± 7.3****
Table 1. Potency of adenosine obtained with whole cell impedance-based experiments performed with U-2 
OS cells after pre-treatment with different ENT1 inhibitors at 1 μM (“Format 1”), and potency (pIC50) and 
inhibitory efficacy of ENT1 inhibitors obtained with whole cell impedance-based experiments performed with 
U-2 OS cells followed by adenosine treatment at 10−4.5 M (“Format 2”). Values are mean ± SEM of at least three 
separate experiments performed in duplicate. aSignificance compared to vehicle’s 1 pEC50 was tested using 
one-way ANOVA with Dunnett’s post-hoc test. ****p < 0.0001. bData are normalized to maximal response of 
adenosine (10−4.5 M) of vehicle 1 (100%). Significance compared to vehicle 1 was tested using one-way ANOVA 
with Dunnett’s post-hoc test. ****p < 0.0001. n.a.: not applicable.
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Figure 3. The response measured is adenosine receptor AR-mediated. (A) A representative response of 
adenosine (10−4.5 M) after pre-treatment with 10−6 M NBTI, CGS15943, PSB1115 or NBTI and CGS15943 
simultaneously. (B) Bar graphs represent the AUC after adenosine addition (normalized to vehicle 1 as 100%). 
Data shown are mean ± SEM from at least three separate experiments performed in duplicate. Significance 
compared to vehicle was tested using one-way ANOVA with Tukey’s multiple comparison post-test. 
****p < 0.0001.
Figure 4. Concentration-dependent effects of ENT1 inhibitors after subsequent AR stimulation with a single 
adenosine concentration (“Format 2”). A representative adenosine response (10−4.5 M) after pre-treatment 
with ENT1 inhibitors, i.e. (A) NBTI, (B) dilazep and (C) dipyridamole. (D) Concentration-response curves of 
ENT1 inhibitors (normalized to the maximal response of adenosine alone (10−4.5 M, 100%)). Data shown are 
mean ± SEM from at least three separate experiments performed in duplicate.
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Discussion
The significance of membrane transporters in drug discovery is widely recognized24 and their in-depth investi-
gation is essential as they play a vital role both in physiological conditions and in many diseases. Unfortunately, 
membrane transporters are vastly understudied compared to other groups of target proteins, and the attention 
they are getting from the scientific community is limited and not indicative of their biological relevance25. One of 
the main reasons is that the available assays to study transporter activity have limitations, as already introduced 
above. For another large membrane-bound protein family, GPCRs, label-free technologies are nowadays fre-
quently used to assess receptor pharmacology26–28. Specifically, it has been shown that agonist-induced adenosine 
receptor signalling causes cell morphology changes that can be monitored via both optical- and impedance-based 
label-free assays29–32. In addition, many efforts to study ion channels with label-free technologies are reported. 
Typical examples are the monitor of TRP ion channel activity with an impedance based assay33, as well as the 
study of GIRK channel and GABAA receptor with an optical biosensor34,35. Of note, as far as membrane trans-
porters are concerned, there is currently a single report in which an optical-based label-free assay (i.e. Epic by 
Corning) is used to study the electrogenic transporter SLC34A22. However, this method has not been applied 
to other electrogenic transporters so far, and still leaves a need for the many non-electrogenic transporters. We 
therefore established an impedance-based assay suitable for investigating the inhibition of non-electrogenic 
membrane transporters via the indirect measurement of GPCR-mediated cell signalling on cells that, in this case, 
endogenously express both targets.
Initial experiments with U-2 OS cells demonstrated that U-2 OS cell line can be used for xCELLigence exper-
iments as they strongly adhere to the bottom of the wells, which is a requirement for impedance measurements36. 
This resulted in a CI, and thus provided a good window of detection for the assay (Fig. 2B). Additionally, radioli-
gand binding assays validated the presence of ENT1 on U-2 OS cell membranes, since, among others, the deter-
mined affinity for all ENT1 inhibitors was found to be in good agreement with available literature data37,38. The 
presence of ARs on U-2 OS cells has already been reported previously, hence it was not re-examined39,40.
As adenosine is the endogenous substrate and agonist of ENT1 and ARs, respectively, it was chosen as the 
compound for assay development. Concentration-response curves of adenosine to cells pre-treated with or with-
out a single concentration of ENT1 inhibitors yielded significant differences on the apparent pEC50 value of aden-
osine (Fig. 2, Table 1). The low pEC50 value of adenosine measured in the absence of ENT1 inhibitor (4.2 ± 0.1), 
might indicate that mainly A2BAR is expressed in this cell line, as potency values for the other ARs are reported 
to be at least 100-fold higher41. This hypothesis is compatible with the data publically available from “The Human 
Protein Atlas” showing that A2B is the most prevalently expressed AR subtype on U-2 OS cells42–45. Moreover, 
pre-treatment of cells with the non-selective ARs antagonist CGS 1594346, led to a large decrease of subsequent 
adenosine signalling, evidence that an AR-specific signal had been captured (Fig. 3), while pre-treatment with 
the selective A2B AR antagonist PSB 1115, resulted in a further decrease of adenosine signalling, confirming the 
hypothesis of A2B AR being the main player in the signalling pathway. It is important to note that intracellular 
adenosine concentrations are strictly regulated to be kept low47,48. Specifically, adenosine kinase (ADK), is the 
principle enzyme to regulate intracellular adenosine and metabolise it to adenosine monophosphate (AMP), 
which could be further phosphorylated to adenosine diphosphate (ADP) and triphosphate (ATP). Consequently, 
the intracellular and extracellular adenosine concentrations will not be equilibrated, leading to a fast and contin-
uous adenosine transportation inside the cell by ENT1. As a result, the extracellular adenosine concentration are 
significantly higher when an ENT1 inhibitor is present.
Subsequent experiments established that the current assay allowed the inhibitory effect of ENT1 inhibitors 
to be measured in two different assay formats: (1) pre-treatment with a fixed concentration of ENT1 inhibi-
tors and subsequent addition of different concentrations of adenosine (Fig. 2) and (2) pre-treatment with differ-
ent concentrations of ENT1 inhibitors and subsequent addition of a single concentration of adenosine (Fig. 4). 
In case of the first format, apparent pEC50 values were obtained for adenosine in the absence and presence 
of different inhibitors, while in the second format the changes of the apparent pEC50 values are caused by a 
concentration-dependent effect of ENT1 inhibitors, which thus are best quantified as pIC50 values for the inhib-
itors. For NBTI, a selective inhibitor of ENT1, a potency value (8.3 ± 0.3) comparable to the radioligand binding 
data (8.7 ± 0.02) (Supplementary Material; Table S1) as well as previously reported data was found49. Dilazep 
appeared to be approximately 10-fold more potent compared to the literature49 and the radioligand binding data, 
which may be explained by the fact that dilazep is a not selective ENT1 and ENT2 inhibitor50. The second format 
also provides information on the inhibitory efficacy of ENT1 inhibitors (i.e. the efficacy of adenosine signalling 
via AR that results from ENT1 inhibition) on adenosine-mediated receptor signalling (Fig. 4D). Here it was 
found that dipyridamole had the highest efficacy, which might be explained by the fact that dipyridamole is a 
non-selective ENT inhibitor, i.e. it has been shown to have high affinity to ENT1, ENT2, ENT3 transporters51 
and lower affinity to ENT452 as well. Together, this could lead to significantly higher extracellular concentrations 
of adenosine that explain dipyridamole’s increased inhibitory efficacy compared to an ENT1 selective inhibitor, 
such as NBTI. In addition, dilazep seems to follow the same trend of increased inhibitory efficacy as it is also a 
non-selective inhibitors for ENT1. Such hypothesis is reinforced by the fact that it has been shown that all ENTs 
are endogenously expressed on U-2 OS cells53–56. The inhibition of ENT2, ENT3 and ENT4 on U-2 OS cells using 
this novel method merits further investigation.
conclusions
In conclusion, we developed and validated an assay to detect SLC activity via GPCR signalling in living cells, using 
a label-free whole cell impedance-based system (xCELLigence), which is to our knowledge the first case where a 
biosensor technology is used to study the activity of inhibitors for non-electrogenic membrane transporters. As 
a proof-of-concept the inhibition of ENT1 via subsequent AR signalling in human osteosarcoma cells (U-2 OS) 
that endogenously express these targets, was studied. We were able to show that its inhibition could be monitored 
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sensitively and quantified accurately via the indirect measurement of adenosine-mediated ARs signalling. Thus, 
this approach offers the possibility to study membrane transporters that are or can be linked to a GPCR via their 
common substrate/ligand. Ultimately, this label-free whole-cell assay technology opens novel opportunities for 
membrane transporter drug discovery.
Methods
Materials and reagents. Dipyridamole was kindly provided by Janssen Pharmaceutics and dilazep was 
obtained from Asta-Werke (Degussa Pharma Gruppe, Bielefeld, Germany). NBTI and adenosine were purchased 
from Sigma-Aldrich (St. Louis, MO, USA), while CGS 15943 was purchased from Tocris Bioscience (Bristol, UK). 
PET E-plates 16 and 96 for the xCELLigence DP and SP system (ACEA Biosciences, San Diego, CA, USA) were 
obtained from Bioké (Leiden, the Netherlands). Homo sapiens bone osteosarcoma cells (U-2 OS) were a kind gift 
from Mr. Hans den Dulk (Leiden Institute of Chemistry, department of Molecular Physiology, Leiden University, 
the Netherlands). All other compounds and materials were obtained from standard commercial sources.
Cell culture. U-2 OS cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 
stable glutamine 10% (v/v) New Born Calf Serum (NBCS), 100 IU/ml penicillin and 100 mg/ml streptomycin 
at 37 °C and 7% CO2. Cells were cultured as a monolayer on 10 cm ø plates and used for whole cell experiments 
when a confluency of ~90% was reached.
Membrane preparation. U-2 OS cells were grown as a monolayer in 15 cm ø plates to 80–90% confluency. 
Then they were detached by scraping into 5 ml of phosphate-buffered saline (PBS) and subsequently centrifuged 
for 5 min at 1500 rpm to remove PBS. The pellets were resuspended in ice-cold 50 mM Tris-HCl buffer, pH 7.4 and 
homogenized with an Ultra Turrax homogenizer (IKA-Werke GmbH & Co.KG, Staufen, Germany). Membranes 
and the cytosolic fraction were separated by centrifugation at 31,000 rpm in an Optima LE-80 K ultracentrifuge 
(Beckman Coulter, Fullerton, CA) at 4 °C for 20 min. The pellet was resuspended in 10 mL of Tris-HCl buffer 
and the homogenization and centrifugation step were repeated. Finally the membrane pellet was resuspended 
in 50 mM Tris-HCl buffer, pH 7.4, and aliquots were stored at −80 °C. Membrane protein concentrations were 
measured using a BCA protein determination57.
Radioligand binding assay. U-2 OS membranes were thawed, homogenized using an Ultra Turrax homog-
enizer at 24,000 rpm (IKA-Werke GmbH & Co.KG, Staufen, Germany) and diluted to the desired concentration 
(6 μg/well) using assay buffer (50 mM Tris-HCl pH 7.4). Displacement experiments were performed using 10 
concentrations of competing ligand in the presence of a final concentration of 4 nM [3H]NBTI. At this concen-
tration, total binding (TB) did not exceeded 10% of the radioligand present in the assay in order to prevent ligand 
depletion. Nonspecific (NSB) binding was determined in the presence of 10−5 M NBTI. Total reaction volume 
was 100 μL and final concentrations of DMSO were ≤0.25%. The experiment was initiated by addition of mem-
branes. Samples were incubated at 25 °C for 60 min to reach equilibrium. The incubation was terminated by rapid 
vacuum filtration over GF/C filter using Brandel Harvester 24w (Brandel, Gaithersburg, MD, USA). Filters were 
subsequently washed three times using ice-cold wash buffer (50 mM Tris-HCl, pH 7.4). After drying the filters at 
55 °C for 30 min, filter-bound radioactivity was determined by liquid scintillation spectrometry using a Tri-Carb 
liquid scintillation counter (PerkinElmer, Groningen, The Netherlands).
Label-free whole-cell assay. Detection principle. Label-free whole-cell assays were performed using the 
xCELLigence real-time cell analyser (RTCA) system8,9, as described previously26. In short, the RTCA system 
measures the electrical impedance generated by cells adhering to gold-coated electrodes embedded on the bot-
tom of microelectronic E-plates. Variations in number, degree of adhesion, cellular viability and morphology of 
cells result in relative changes in impedance (Z), which are recorded continuously at 10 kHz and displayed in the 
unitless parameter coined Cell Index (CI)7,8. CI is a relative measure defined as (Zi-Z0) Ω/15 Ω, where Zi is the 
impedance at each individual time point and Z0 represents the baseline impedance in the absence of cells, which 
is measured prior to the start of the experiment.
General Protocol. U-2 OS cells were harvested by re-suspending in cell culture medium after brief trypsini-
zation (treatment with trypsin/EDTA for about 5 min) and centrifuged once at 200 × g (1500 rpm) for 5 min. 
Background impedance (Z0) was measured after the addition of 40 μL culture media to 16 or 96 well E-plates. 
Cells were seeded by adding 50 μL of cell suspension containing 20,000 cells per well. After resting at room tem-
perature for at least 30 min, the E-plate was placed into the recording station situated in a 37 °C and 5% CO2 
incubator. Impedance was measured every 15 minutes overnight.
Cell pre-treatment: Cells were pre-treated by an ENT1 inhibitor (10−6 M or 10−6 to 10−11 M, depending on the 
assay), adenosine receptor antagonist or vehicle control (0.25% dimethylsulfoxide (DMSO) in Phosphate-buffered 
saline (PBS)) in 5 µl after 18 h. CI was recorded for at least 30 minutes with a recording schedule of 15 second 
intervals for 20 minutes, followed by intervals of 1 minute.
Cell treatment: Afterwards, cells were stimulated with adenosine (10−4.5 or 10−6 to 10−3.5 M depending on 
the assay) or vehicle control (0.125% DMSO in PBS) in 5 μL and CI was recorded for at least 90 minutes with a 
recording schedule of 15 second intervals for 20 minutes, followed by intervals of 1 minute for 10 minutes and 
finally 5 minutes. In all cases, final well volumes and DMSO concentrations upon cell and ligands addition were 
100 μL and 0.375%, respectively, for all wells and assays.
Data analysis. Radioligand binding assay. Data analyses were performed using GraphPad Prism 7.0 soft-
ware (GraphPad Software Inc., San Diego, CA, USA). pIC50 values in radioligand displacement assays were 
obtained by non-linear regression curve fitting into a sigmoidal concentration-response curve using the equation:
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= + − + − .∧ XY Bottom (Top Bottom)/(1 10 ( LogIC50))
pKi values were acquired from pIC50 values using the Cheng-Prusoff equation58:
= +K IC /(1 [radioligand]/K )i 50 D
The KD value of 1.89 nM for [3H] NBTI, was obtained by fitting the data from homologous displacement 
experiments (Supplementary Material; Fig. S1) to the model “One site – Homologous”.
Label-free whole-cell assay. RTCA software 2.0 (ACEA Biosciences, Inc.) was used to obtain the experimental 
data. All data were analysed using GraphPad Prism 7.00 (GraphPad software, San Diego, CA, USA). After sub-
tracting baseline (vehicle control), ligand responses were normalized at the time of ligand addition to obtain Δ 
Cell Index (Δ CI) values to correct for ligand-independent responses. Cells that were not pre-treated were used 
as control (vehicle 1) for the ENT1 inhibitor addition, while cells that were not treated with adenosine (vehicle 2) 
were used as control for the adenosine addition. The time of normalization was either 18 h or 18 h 30 min after cell 
seeding for analysis of ENT1 inhibitor/ARs antagonist or adenosine effects, respectively.
The absolute values of Total Area Under the Curve (AUC) up to 90 min after adenosine addition were exported 
to Graphpad Prism for further analysis yielding bar graphs or concentration–response curves. pEC50 values of 
adenosine after pre-treatment of cells with one concentration of ENT1 inhibitors (format 1; Table 1) and pIC50 
values of ENT1 inhibitors (format 2; Table 1) were obtained using non-linear regression curve fitting of Total 
AUC data into a sigmoidal dose-response curve with variable slope. Data shown are the mean ± SEM of at least 
three individual experiments performed in duplicate.
Statistical significance was determined using one-way ANOVA, followed by a Tukey’s post test for comparison 
of all columns or a Dunnett’s post test when comparing to vehicle. If p-values were below 0.05, observed differ-
ences were considered statistically significant.
Data Availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
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